Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $72.
Raymond James analyst Tiago Fauth initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $72.